Latest news with #JohnJacobs
Yahoo
28-05-2025
- Business
- Yahoo
Solana, Tucson's Newly Restored Historic Boutique Guest Ranch is Expanding
Sold-Out Spanish Villas, 5-Star Reviews, and a Wellness-Focused Expansion—Solana Becomes the Wild West's Newest Luxury Escape TUCSON, Ariz., May 28, 2025 (GLOBE NEWSWIRE) -- Something extraordinary is happening in Tucson's Tanque Verde Valley. A hidden gem with the soul of the Southwest and the service of a boutique luxury guest ranch is quietly making an entrance on to the hospitality stage — and it's doing it with a cowboy hat and dusty boots!Solana Spanish Villas, Tucson's newly restored upscale guest ranch, has achieved what few boutique properties ever do: a near 100% occupancy YTD in 2025, rave reviews across every platform, and a loyal following of travelers booking over a year in advance. With its authentic Tucson dude ranch spirit, tastefully modernized Spanish-style villas, and jaw-dropping natural surroundings, Solana isn't just a place to stay—it's an experience guests can't stop talking about. 'There's nothing like Solana anywhere in Tucson—or Southern Arizona,' says owner John Jacobs, who, along with wife Danielle Jacobs, professionally manages the estate with full-time, on-site staff. 'We built Solana to offer something rare: the charm and history of an old-world guest ranch combined with today's luxury, service, and style.' The venture has been so successful that the Jacobs have acquired the adjacent historic 5.4 acre farrier school and calf-roping ranch from well-known Tanque Verde horseman, George Goode to expand Solana to over 11 acres. The new Solana Ranch offers a more rustic taste of Tanque Verde with a large hacienda club house for hosting wellness and yoga retreats in Tucson, expanded lodging for Tucson corporate retreats, luxury conestoga glamping wagons coming in late 2025, and the natural desert ambiance of horses and bonfires under the into 2026, the new Solana Guest Ranch will expand the property to: Lodging for 100+ guests Conestoga glamping wagons with A/C and private bathrooms Onsite yoga platforms and desert wellness amenities Private chef-prepared meals and curated retreat experiences Corporate event spaces and planning services Danielle Jacobs, a Tucson native, successful entrepreneur, business executive, designer and event planner, works directly with organizations to coordinate unforgettable events. Whether it's a high-impact executive offsite, a yoga school's seasonal retreat, or an all-inclusive wellness weekend, Solana's team brings personalized service, event planning, and food & beverage coordination to the next level. A Desert Retreat Unlike Any Other Tucked beneath the shade of towering eucalyptus trees and framed by the rugged peaks of the Rincon and Catalina Mountains, Solana Spanish Villas sits on a historic 5.7-acre estate once known as the Bar J Desert Haciendas—a guest ranch that dates back to the 1940s. Today, it's been reimagined with designer furnishings, gourmet kitchens, fire pits, a koi pond, pickleball court, resort-style pool, and desert trails that seem to whisper Old West secrets. And in their first summer of 2025, Solana is offering a jaw-dropping $99/night staycation deal for locals looking to experience the magic. 'It's our way of giving back to Tucson,' says Danielle. 'We're booked solid year-round, but we're holding back just a few rooms for family reunions and corporate retreats. We want to keep our roots in this community.' Activities at Solana Spanish Villas Guests at Solana Spanish Villas enjoy far more than just a comfortable stay—they experience a mini-resort escape in the scenic Tanque Verde Valley. Guests can relax poolside under palm trees, relax on the dock by the pond, or challenge friends to games of pickleball, basketball, garden chess, and cornhole. For those seeking serenity, the property features walking paths under towering eucalyptus, quiet corners for birdwatching, and a tranquil dock for reflection. Families and groups can gather at fire pits with swings, enjoy BBQs. With spacious villas and casitas, full kitchens, and private patios, Solana also offers resort-style amenities including yoga mats, games, and books in each villa. The combination of relaxation, recreation, and convenience makes it ideal for family reunions in Tucson, wellness retreats, or extended stays. What's Next? Solana Tucson Becomes a Wellness Destination Solana's rise isn't a fluke—it's purpose driven and on trend. As Southern Arizona continues to attract travelers seeking meaningful, nature-rooted experiences, event weddings, and wellness escapes, Solana stands apart with immersive geo-travel, curated wellness, and the kind of hospitality that feels as personal as it is professional. Similar to the much larger Canyon Ranch or Miraval Spa, the intimate Solana Ranch model focuses on immersion of place. 'Our guests don't always want a basic hotel room,' says Danielle Jacobs. 'More and more guests are seeking a memorable experience. They want connection. They want to feel like they're somewhere real. Solana delivers this—and more.' With limited availability and a waitlist already forming for 2026 retreats, Solana Spanish Villas and the new Solana Guest Ranch have officially become one of Southern Arizona's most in-demand reserve a stay, plan a wellness weekend, or pre-book a 2026 special event call (520) 200-2059: 10700 E Tanque Verde Road, Tucson, AZ 85749 Solana is a fully independent, locally owned guest ranch—not affiliated with Tanque Verde Guest Ranch, Canyon Ranch or Miraval. The property's roots as a guest ranch stretch back 77 years to 1948 and are being preserved and expanded for a new generation of travelers. Photos accompanying this announcement are available at: in to access your portfolio
CNN
22-05-2025
- Health
- CNN
After delay, FDA approves Novavax's Covid-19 vaccine, but only for older people and those at high risk
After a six-week delay, the US Food and Drug Administration has approved Novavax's Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who have at least one underlying condition that puts them at higher risk of severe illness. 'Market research and US C.D.C. statistics indicate that older individuals and those with underlying conditions are the populations most likely to seek out COVID-19 vaccination seasonally,' Novavax President and CEO John Jacobs said in a statement Saturday. 'This significant milestone demonstrates our commitment to these populations and is a significant step towards availability of our protein-based vaccine option.' The US Centers for Disease Control and Prevention lists a wide range of conditions that may make someone more likely to become severely ill with Covid-19, including older age, asthma, diabetes, lung disease, obesity and pregnancy. The Novavax Covid-19 vaccine, which uses more traditional protein-based technology than the mRNA vaccines from Pfizer/BioNTech and Moderna, has been subject to emergency use authorization since 2022. Pfizer and Moderna's vaccines have been FDA-approved for people 12 and up and remain available under emergency use authorization for children as young as 6 months. Novavax's vaccine had been on track for full approval April 1, but the FDA delayed the decision while it sought more data, a source told CNN. The new approval letter issued Friday requires Novavax to conduct postmarketing studies looking at the risk of myocarditis and pericarditis – inflammation of the heart muscle and of the membrane surrounding the heart – in people who receive the vaccine. These conditions have rarely been reported after Covid-19 vaccination, according to the US Centers for Disease Control and Prevention. A handful of cases were reported in trials of the Novavax vaccine, suggesting an increased risk, the CDC notes. However, the CDC and its Advisory Committee on Immunization Practices have said the benefits of Covid-19 vaccination outweigh the rare risk of heart inflammation in all groups recommended for vaccination. The CDC's vaccine advisers are considering changes to the agency's guidance for who should get an annual Covid-19 shot. At last month's meeting of, the committee discussed a recommendation focused on older adults, those with weakened immune systems and possibly those who are more likely to be exposed to the coronavirus. Robert F. Kennedy Jr., secretary of the US Department of Health and Human Services and a longtime anti-vaccine activist, has falsely called vaccines for Covid-19 'the deadliest vaccine ever made' and more recently made misleading statements about the safety of the measles vaccine amid a massive outbreak centered in West Texas. HHS did not respond to a request for comment on the Novavax approval.
Miami Herald
21-05-2025
- Health
- Miami Herald
FDA approves Novavax's COVID-19 vaccine with limitations
The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay. The agency approved the vaccine only for people 65 and older and those 12 and older with at least one underlying condition in which they are at a higher risk of severe illness. The company is based in Gaithersburg, Maryland. The conditions include older age, asthma, diabetes, lung disease, obesity and pregnancy. 'Market research and US C.D.C. statistics indicate that older individuals and those with underlying conditions are the populations most likely to seek out COVID-19 vaccination seasonally,' Novavax President and CEO John Jacobs said in a statement Saturday to CNN. 'This significant milestone demonstrates our commitment to these populations and is a significant step towards availability of our protein-based vaccine option.' The Novavax Covid-19 vaccine has had emergency use authorization since 2022 and an updated version was approved in August 2924. The brand name is Nuvaxovid. The FDA granted Pfizer-BioNTech full approval for those 12 and older in August 2021 and Moderna in January 2022. They remain available under emergency use authorization for children as young as 6 months. Novavax uses more traditional protein-based technology than the mRNA vaccines of Pfizer and Moderna. Pfizer was the first COVID-19 vaccine to receive emergency approval in December 2020 and Moderna was followed on week later. The first COVID-19 case was reported in the United States on Jan. 20, 2020. The CDC no longer tracks cases but examines SARS-CoV-2 levels in sewage, and limited data from hospitals and states. Cases now are hard to track because most people get tests at home, and the results are not reported to state health agencies. About 23% of U.S. adults are estimated to be up to date with the vaccine, according to the CDC through April. For children 6 months and up to 18 it is an estimated 13.0%, the CDC reported. With Robert F. Kennedy Jr., a vaccine skeptic, leading Health and Human Services, the FDA and CDC are giving greater scrutiny to the shots. The FDA delayed the decision on the vaccine as it sought more data, a source told CNN. In the approval letter issued Friday, Novavax must conduct postmarketing studies looking at the risk of myocarditis and pericarditis in people who receive the vaccine. These are inflammation of the heart muscle and the membrane surrounding the heart. Only a few cases were reported in the 30,000-person clinical of the Novavax vaccine, the CDC notes. But the CDC and its Advisory Committee on Immunization Practices have said the benefits of the vaccination outweigh the rare risk of heart inflammation in all groups recommended for vaccination. The CDC is considering whether to only recommend yearly vaccines for older people or ones with a compromised immune function. Everyone 6 months of age and older are now recommended to get the yearly dose. Copyright 2025 UPI News Corporation. All Rights Reserved.
Yahoo
19-05-2025
- Business
- Yahoo
Novavax Shares Jump 17% FDA Grants Full Approval to COVID Vaccine
Novavax (NASDAQ:NVAX) shares jumped more than 17% on Monday after the U.S. Food and Drug Administration granted full approval to its COVID-19 vaccine, Nuvaxovid, for adults aged 65 and older. The shot, previously authorized for emergency use, also becomes commercially available for individuals aged 12 to 64 with underlying health conditions that heighten the risk of severe illness. Warning! GuruFocus has detected 4 Warning Signs with NVAX. Developed with Sanofi (NASDAQ:SNY), the protein-based vaccine is an alternative to existing mRNA options. Sanofi will now lead commercialization efforts and pay Novavax a $175 million milestone fee tied to the FDA's approval. Novavax expects additional revenue through future royalties as the vaccine rolls out in upcoming seasons. The company aims to begin commercial delivery of its 20252026 version this fall. CEO John Jacobs said demand could be robust, citing health data indicating older adults and those with medical vulnerabilities are most likely to seek seasonal COVID-19 shots. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
19-05-2025
- Business
- Yahoo
Novavax Shares Jump 17% FDA Grants Full Approval to COVID Vaccine
Novavax (NASDAQ:NVAX) shares jumped more than 17% on Monday after the U.S. Food and Drug Administration granted full approval to its COVID-19 vaccine, Nuvaxovid, for adults aged 65 and older. The shot, previously authorized for emergency use, also becomes commercially available for individuals aged 12 to 64 with underlying health conditions that heighten the risk of severe illness. Warning! GuruFocus has detected 4 Warning Signs with NVAX. Developed with Sanofi (NASDAQ:SNY), the protein-based vaccine is an alternative to existing mRNA options. Sanofi will now lead commercialization efforts and pay Novavax a $175 million milestone fee tied to the FDA's approval. Novavax expects additional revenue through future royalties as the vaccine rolls out in upcoming seasons. The company aims to begin commercial delivery of its 20252026 version this fall. CEO John Jacobs said demand could be robust, citing health data indicating older adults and those with medical vulnerabilities are most likely to seek seasonal COVID-19 shots. This article first appeared on GuruFocus. Sign in to access your portfolio
